News Archives - Page 1425 of 1434

ThursdayNov 03, 2016 11:29 am

Curis, Inc. (CRIS) Posts Wider Q3 Loss; Shares Higher

Shares of Curis (NASDAQ: CRIS) this morning posted a third quarter net loss of $28.3 million, or $(0.21) per share, on revenues of $1.8 million vs. a net loss of $5.5 million, or $(0.04) per share, on revenues of $2.0 million for the third quarter of 2015. The net loss for the 2016 quarter includes a non-cash in-process research and development charge of $18.0 million related to the amendment of Curis's license agreement with Aurigene. To view the full press release, visit: http://nnw.fm/3uHzF About Curis, Inc. Curis is a biotechnology company focused on the development and commercialization of innovative and…

ThursdayNov 03, 2016 11:28 am

Achillion Pharmaceuticals, Inc. (ACHN) Posts Q3, Nine-Month Results; Shares Tumble

Shares of Achillion Pharmaceuticals (NASDAQ: ACHN) are sharply lower after the company reported its third quarter and nine-month financial results. Achillion posted a third-quarter net loss of $20.7 million or $0.15 per share, compared with net income of $26.3 million or $0.19 per share for the third quarter of 2015. For the nine months ended September 30, 2016, Achillion reported a net loss of $57.3 million, compared to a net loss of $22.0 million in the same period in 2015. The company also said it will present at the 58th Annual Meeting of the American Society of Hematology (ASH) in San…

ThursdayNov 03, 2016 11:26 am

BioLineRx Ltd. (BLRX) Announces Positive Data for BL-8040 Oncology Platform; Shares Inch Higher

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is trading higher after the company reported positive results for BL-8040, its leading oncology platform, that will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exhibition in San Diego taking place December 3-6, 2016. “In particular, clinical studies show that BL-8040 acts selectively on chemotherapy-resistant cells, which may be beneficial in reduction of residual disease and supports the incorporation of BL-8040 in front-line treatment settings such as AML consolidation. Such studies are currently ongoing. We are also encouraged to see, in pre-clinical models, a synergistic effect between BL-8040 and Venetoclax, and…

WednesdayNov 02, 2016 10:51 am

Verastem, Inc. (VSTM) Licenses Infinity Pharmaceuticals’ (INFI) Cancer Treatment Candidate

Verastem, Inc. (NASDAQ: VSTM) and Infinity Pharmaceuticals (NASDAQ: INFI) are trading higher after the companies announced that Verastem has licensed exclusive worldwide rights to develop and commercialize Infinity's oncology product candidate duvelisib for the treatment of hematologic cancers, including chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma (iNHL) and T cell lymphomas. To view the full press release, visit: http://nnw.fm/WM3ut About Verastem, Inc. Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its…

WednesdayNov 02, 2016 10:50 am

Agora Holdings, Inc. (AGHI) Continues to Advance FRAME Social Media Management Tool

Agora Holdings (OTC: AGHI) continues to update its FRAME social media management software offered by its Geegle Media subsidiary, and most recently announced its plans to move the platform from the private market to a unique “do it yourself” tool for small and medium-sized businesses. “Originally launched in September of this year, FRAME differentiates itself from the competition by offering free use for non-commercial users. In an effort to provide the best experience possible to both free and paid users, FRAME also offers an extensive reporting system that allows users to monitor the performance metrics of each of their posts…

WednesdayNov 02, 2016 10:49 am

Cherubim Interests, Inc. (CHIT) Sharply Reduces Debt, Shares Lower

Cherubim Interests (OTC: CHIT) this morning announced the elimination of a “significant” portion of its High Interest Convertible Debt and Principal Debt in what company CEO Patrick Johnson says is the result of an aggressive debt reduction campaign. “We have been aggressively addressing debt reduction over the past twelve months. These debts included convertible note instruments to extremely high interest lenders, which upon conversion causes dilution that adversely affects the stock price," he stated in the news release. "The approximate debt as of August 31, 2015, was $1,180,000 and to better position the company for uplist we have retired over…

WednesdayNov 02, 2016 10:47 am

MicroVision, Inc. (MVIS) Posts Q3, Nine-Month Revenue Growth, Reaffirms FY Sales; Shares Surge

MicroVision (NASDAQ: MVIS) is up 10% in morning trade after the company posted third-quarter revenue of $4.0 million and a 61% increase in nine-month revenue to $11.9 million. Net loss for the third quarter of 2016 was $4.1 million, or $0.08 per share, compared to $3.5 million, or $0.07 per share, for the same quarter a year ago. MicroVision reaffirmed its revenue guidance for full-year 2016, with expectations at the high end of $14.5 million and $15 million. The innovator of ultra-miniature projection display and sensing technology also announced its plans to roll-out three new scanning engine products starting in…

WednesdayNov 02, 2016 10:45 am

EyeGate Pharmaceuticals, Inc. (EYEG) Records Q3 Revenues; Shares Higher

EyeGate Pharmaceuticals (NASDAQ: EYEG) this morning reported third-quarter revenue of $0.274 million, compared with no revenue in the third quarter of 2015. Net loss for the quarter was $3.3 million, compared with a loss of $1.3 million in the comparable quarter of last year. The company attributes the loss to its confirmatory phase 3 trial of EGP-437 in anterior uveitis, its phase 1b/2a trial for post-cataract surgery inflammation and pain and the continued development of the EyeGate OBG, as well as increased R&D, general and administrative and other expenses supporting these activities. To view the full press release, visit: http://nnw.fm/1JApy…

TuesdayNov 01, 2016 2:01 pm

PharmaCyte Biotech (PMCB) Files Request for Pre-IND of Pancreatic Cancer Clinical Trial; Shares Climb

PharmaCyte Biotech (OTCQB: PMCB) is trading higher after the clinical-stage biotech announced its first steps toward regulatory approval in the U.S. of the company’s therapy for inoperable pancreatic cancer (LAPC). The company has filed a request for a pre-IND meeting with the U. S. Food and Drug Administration (FDA) for its planned clinical trial designed to meet a clear unmet medical need for those whose cancer no longer responds after 4-6 months of treatment with the combination of Abraxane® plus gemcitabine. The trial will be open-label and multi-site in nature, with sites in the U.S. and Europe. To view the…

TuesdayNov 01, 2016 11:22 am

Skyline Medical, Inc. (SKLN) Inks UK Distribution Deal with GLG Pharma; Shares Surge

Shares of Skyline Medical (NASDAQ: SKLN) are up 27% after the producer of the FDA-approved STREAMWAY® System announced its distribution agreement granting GLG Pharma, LLC (“GLG”) exclusive rights to market and distribute the STREAMWAY® System in the UK. STREAMWAY System is the company’s direct-to-drain fluid disposal system designed to automate the collection, measurement and disposal of waste fluids in medical settings. To view the full press release, visit: http://nnw.fm/mF2cy About Skyline Medical Inc. Skyline Medical Inc. produces a fully automated, patented, FDA-cleared, waste fluid disposal system that virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Breaks Categories: News